Complete your Myeloma diagnostic tools with Sebia FLC Assay
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
Abnormally higher levels of serum free light chains and abnormal kappa to lambda ratios are found in the majority of Multiple Myeloma cases. The severity of disease correlates with the elevation and abnormal ratio of these free light chains. These values and ratios are widely used to determine the prognosis and to monitor the disease activity and response to therapy. They provide important clues to clinicians which might help them tailor the treatment protocols and make future therapeutic plans.
Current Nephelometric and turbidimetric based have been shown to overestimate the sFLC levels that are not always consistent with Serum Protein Electrophoresis/Immunofixation and other clinical parameters.
That is why Sebia has developed an ELISA test for measuring sFLC based on proven and recognized technology. The Sebia FLC Assay is the only test that provides sFLC concentrations close to those obtained by SPE in the presence of an FLC peak, and that has a lower retest rate than current tests.
Download our leaflet and discover analytical & clinical performance values of Sebia FLC test.
Test associated with this resource
Related instrument
Featured resources on FLC
Educational Webinar with Pr. Oliver Frey
Educational webinar with Dr. Maria Willrich and Dr. Angela Dispenzieri
Educational Workshop with Pr Giovanni Palladini
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.